Consumer Discretionary • Specialty Chemicals
$88.67 ▲ +1.83
(+2.11%)
MKT CAP: $10.72B • VOL: 3.68M
52W L $79 52W H $129
CLX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-06-30 | FY 2024
FILED 2024-06-30 | FY 2023
FILED 2023-06-30 |
|---|---|---|---|
| Revenue (Total Sales) | $7.10B | $7.09B | $7.39B |
| YoY Revenue Growth % | +0.2% | -4.0% | — |
| Gross Profit | $3.21B | $3.05B | $3.25B |
| Gross Margin % | 45.2% | 43.0% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $972.3M | $344.6M | $190.0M |
| Operating Margin % | 13.7% | 4.9% | 2.6% |
| Net Income (GAAP) | $824.0M | $292.0M | $161.0M |
| EBITDA (Normalized) | $1.15B | $514.2M | $456.0M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $981.0M | $695.0M | $1.16B |
| Capital Expenditures (CapEx) | $220.0M | $212.0M | $332.5M |
| Free Cash Flow (FCF) | $761.0M | $483.0M | $825.5M |
| FCF Margin % | 10.7% | 6.8% | 11.2% |
| Return on Invested Capital (ROIC %) | 36.0% | 12.6% | 2.8% |
| Cash & Short-Term Equivalents | $227.0M | $290.0M | $975.3M |
| Total Debt (Short + Long Term) | $2.49B | $2.48B | $2.07B |
| Total Stockholders' Equity | -$125.0M | -$41.0M | $4.26B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CLX.